Acarix A/S (ACARIX) - Net Assets
Based on the latest financial reports, Acarix A/S (ACARIX) has net assets worth Skr36.95 Million SEK (≈ $3.98 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr43.50 Million ≈ $4.68 Million USD) and total liabilities (Skr6.55 Million ≈ $704.67K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how strategically is Acarix A/S's equity deployed to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr36.95 Million |
| % of Total Assets | 84.95% |
| Annual Growth Rate | 8.78% |
| 5-Year Change | -62.04% |
| 10-Year Change | -75.46% |
| Growth Volatility | 343.63 |
Acarix A/S - Net Assets Trend (2014–2025)
This chart illustrates how Acarix A/S's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see ACARIX market cap.
Annual Net Assets for Acarix A/S (2014–2025)
The table below shows the annual net assets of Acarix A/S from 2014 to 2025. Also explore ACARIX shareholders equity momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr38.17 Million ≈ $4.11 Million |
-49.57% |
| 2024-12-31 | Skr75.70 Million ≈ $8.15 Million |
+45.89% |
| 2023-12-31 | Skr51.88 Million ≈ $5.58 Million |
+0.12% |
| 2022-12-31 | Skr51.83 Million ≈ $5.58 Million |
-48.46% |
| 2021-12-31 | Skr100.54 Million ≈ $10.82 Million |
+22.41% |
| 2020-12-31 | Skr82.14 Million ≈ $8.84 Million |
+7.22% |
| 2019-12-31 | Skr76.60 Million ≈ $8.24 Million |
-12.83% |
| 2018-12-31 | Skr87.88 Million ≈ $9.46 Million |
-31.85% |
| 2017-12-31 | Skr128.94 Million ≈ $13.88 Million |
-17.09% |
| 2016-12-31 | Skr155.52 Million ≈ $16.74 Million |
+1181.13% |
| 2015-12-31 | Skr12.14 Million ≈ $1.31 Million |
-19.73% |
| 2014-12-31 | Skr15.12 Million ≈ $1.63 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Acarix A/S's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 60046800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr11.65 Million | 30.51% |
| Other Comprehensive Income | Skr2.44 Million | 6.39% |
| Other Components | Skr686.27 Million | 1797.88% |
| Total Equity | Skr38.17 Million | 100.00% |
Acarix A/S Competitors by Market Cap
The table below lists competitors of Acarix A/S ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sanatana Resources
V:STA
|
$26.71 Million |
|
CPI Aerostructures Inc
NYSE:CVU
|
$26.71 Million |
|
Eildon Capital Group
AU:EDC
|
$26.72 Million |
|
Yeong Guan Energy Technology Group Co Ltd
TW:1589
|
$26.73 Million |
|
Global Menkul Degerler AS
IS:GLBMD
|
$26.69 Million |
|
ATA Creativity Global
NASDAQ:AACG
|
$26.69 Million |
|
Pritika Auto Industries Limited
NSE:PRITIKAUTO
|
$26.69 Million |
|
Local Bounti Corp
NYSE:LOCL
|
$26.67 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Acarix A/S's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 75,697,000 to 38,171,000, a change of -37,526,000 (-49.6%).
- Net loss of 48,091,000 reduced equity.
- Share repurchases of 11,105,000 reduced equity.
- New share issuances of 11,105,000 increased equity.
- Other comprehensive income decreased equity by 2,774,000.
- Other factors increased equity by 13,339,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-48.09 Million | -125.99% |
| Share Repurchases | Skr11.11 Million | -29.09% |
| Share Issuances | Skr11.11 Million | +29.09% |
| Other Comprehensive Income | Skr-2.77 Million | -7.27% |
| Other Changes | Skr13.34 Million | +34.95% |
| Total Change | Skr- | -49.57% |
Book Value vs Market Value Analysis
This analysis compares Acarix A/S's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.17x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.28x to 6.17x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | Skr0.75 | Skr0.21 | x |
| 2015-12-31 | Skr0.56 | Skr0.21 | x |
| 2016-12-31 | Skr5.96 | Skr0.21 | x |
| 2017-12-31 | Skr2.81 | Skr0.21 | x |
| 2018-12-31 | Skr1.73 | Skr0.21 | x |
| 2019-12-31 | Skr2.02 | Skr0.21 | x |
| 2020-12-31 | Skr0.77 | Skr0.21 | x |
| 2021-12-31 | Skr0.60 | Skr0.21 | x |
| 2022-12-31 | Skr0.20 | Skr0.21 | x |
| 2023-12-31 | Skr0.11 | Skr0.21 | x |
| 2024-12-31 | Skr0.08 | Skr0.21 | x |
| 2025-12-31 | Skr0.03 | Skr0.21 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Acarix A/S utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -125.99%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -653.32%
- • Asset Turnover: 0.15x
- • Equity Multiplier: 1.27x
- Recent ROE (-125.99%) is below the historical average (-83.84%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -127.02% | 0.00% | 0.00x | 1.21x | Skr-20.72 Million |
| 2015 | -102.09% | 0.00% | 0.00x | 1.28x | Skr-13.61 Million |
| 2016 | -31.02% | 0.00% | 0.00x | 1.11x | Skr-63.79 Million |
| 2017 | -23.09% | -4667.08% | 0.00x | 1.04x | Skr-42.67 Million |
| 2018 | -48.10% | -4128.03% | 0.01x | 1.08x | Skr-51.06 Million |
| 2019 | -60.65% | -2501.83% | 0.02x | 1.08x | Skr-54.12 Million |
| 2020 | -50.58% | -1914.65% | 0.02x | 1.10x | Skr-49.76 Million |
| 2021 | -51.52% | -1377.71% | 0.03x | 1.18x | Skr-61.86 Million |
| 2022 | -148.55% | -1322.31% | 0.08x | 1.34x | Skr-82.17 Million |
| 2023 | -150.02% | -1247.22% | 0.10x | 1.21x | Skr-83.03 Million |
| 2024 | -87.44% | -1067.19% | 0.08x | 1.07x | Skr-73.76 Million |
| 2025 | -125.99% | -653.32% | 0.15x | 1.27x | Skr-51.91 Million |
Industry Comparison
This section compares Acarix A/S's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $854,743,171
- Average return on equity (ROE) among peers: -62.14%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Acarix A/S (ACARIX) | Skr36.95 Million | -127.02% | 0.18x | $26.71 Million |
| Arcoma AB (ARCOMA) | $40.83 Million | -24.05% | 0.67x | $11.70 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $386.69 Million | 4.20% | 0.66x | $51.95 Million |
| BICO Group AB (BICO) | $6.80 Billion | -3.37% | 0.43x | $165.40 Million |
| Boule Diagnostics AB (BOUL) | $169.99 Million | 17.80% | 0.65x | $10.41 Million |
| CellaVision AB (CEVI) | $183.52 Million | 28.78% | 0.20x | $418.90 Million |
| Clinical Laserthermia Systems AB (publ) (CLS-B) | $43.53 Million | -183.31% | 0.33x | $9.40 Million |
| Chordate Medical Holding AB (CMH) | $29.55 Million | -46.39% | 0.39x | $29.05K |
| C-Rad AB (publ) (CRAD-B) | $29.82 Million | -34.38% | 0.50x | $119.27 Million |
| Duearity AB (DEAR) | $6.06 Million | -318.56% | 0.99x | $331.97K |
About Acarix A/S
Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease rule-out. The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to support clinical decision making at the point of care. It sells its products in the Nordic countries, the United Kingdom, Germany, Switzerland, Au… Read more